Trial Profile

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OP 3136 (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Olema Pharmaceuticals

Most Recent Events

25 Apr 2025 According to Olema Oncology media release, patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor types.
23 Jan 2025 Status changed from planning to recruiting.
09 Dec 2024 According to Olema Oncology media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OP-3136

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com